ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 36 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $182,000 | +24.7% | 17,013 | 0.0% | 0.08% | +20.6% |
| Q2 2021 | $146,000 | -18.9% | 17,013 | 0.0% | 0.06% | -12.5% |
| Q1 2021 | $180,000 | -15.9% | 17,013 | 0.0% | 0.07% | -25.8% |
| Q4 2020 | $214,000 | +42.7% | 17,013 | 0.0% | 0.10% | +3.2% |
| Q3 2020 | $150,000 | +54.6% | 17,013 | +70.1% | 0.09% | +49.2% |
| Q2 2020 | $97,000 | +234.5% | 10,000 | 0.0% | 0.06% | +186.4% |
| Q1 2020 | $29,000 | -23.7% | 10,000 | 0.0% | 0.02% | -4.3% |
| Q4 2019 | $38,000 | -5.0% | 10,000 | 0.0% | 0.02% | -14.8% |
| Q3 2019 | $40,000 | -4.8% | 10,000 | 0.0% | 0.03% | -3.6% |
| Q2 2019 | $42,000 | – | 10,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |